Verticillin A-mediated inhibition of MLL1 reduced H3K4me3 levels in the CD274 promoter and PD-L1 expression in tumor cells, coupled with anti-PD-1/PD-L1 antibody immunotherapy, effectively curtailed pancreatic tumor growth [196]. Here, KMT2A is linked to pancreatic neoplasm.